When hair suddenly seems thinner after starting tirzepatide or another GLP-1 medication, it is easy to assume the medication is the entire reason.
But sometimes there is more than one process occurring.
A common question is:
“My hair was already thinning, but it got much worse after I started tirzepatide. Is the medication causing it?”
Recently, a 44-year-old woman came to our dermatology practice with generalized, moderate hair loss that had gradually progressed for years.
Six months earlier, she had started micro-dosing tirzepatide and felt that her shedding and thinning had become noticeably worse.
She had previously tried supplements including Nutrafol and Xtresse without satisfactory improvement and was not currently using a medical hair-loss treatment.
Based on her history and scalp examination, the clinical impression favored telogen effluvium (TE) unmasking underlying androgenetic alopecia (AGA), or female pattern hair loss.
After reviewing several treatment options, she elected to begin low-dose oral minoxidil and spironolactone.
Can Tirzepatide Cause Hair Loss?
Hair shedding has been reported by some patients during treatment with GLP-1–based medications, but the relationship is not always as simple as saying the medication directly damages hair follicles.
In this patient's case, she had already experienced gradual hair loss for years before beginning tirzepatide.
That history is important.
Her dermatologist favored a scenario in which increased shedding consistent with telogen effluvium may have made pre-existing androgenetic alopecia more noticeable.
In other words, tirzepatide was considered a possible exacerbating factor—not proof of the underlying cause of her longstanding patterned thinning.
What Is Telogen Effluvium?
Telogen effluvium, or TE, is a form of increased shedding that can occur when more follicles than usual transition into the resting phase of the hair cycle.
Patients often describe:
More hair in the shower
Increased shedding while brushing
Hair collecting on clothing
A suddenly smaller ponytail
Diffuse loss of volume
TE can occur after a variety of physiologic stressors.
When it happens in someone who already has female pattern hair loss, the sudden reduction in density may make the underlying AGA much easier to see.
What Does “TE Unmasking AGA” Mean?
Imagine that a woman has been slowly losing density from androgenetic alopecia for several years.
The change may be so gradual that she barely notices it.
Then a period of increased shedding occurs.
Suddenly, the scalp becomes more visible and the part appears wider.
The newer shedding did not necessarily create the underlying androgenetic alopecia. Instead, it may have revealed thinning that was already developing.
That was the clinical concern in this patient's case.
How Is Female Pattern Hair Loss Different From Temporary Shedding?
The two conditions behave differently.
Telogen effluvium typically produces increased diffuse shedding.
Androgenetic alopecia involves progressive miniaturization of genetically susceptible follicles.
Women with AGA often notice:
Gradually reduced density
A widening center part
Thinning over the crown
Increased scalp visibility
A smaller ponytail
Preservation of the frontal hairline compared with typical male pattern loss
It is also possible to have both conditions simultaneously.
That distinction matters because simply waiting for a shedding episode to improve may not adequately address underlying progressive AGA.
Why Might Hair Shedding Occur During GLP-1 Treatment?
Hair changes occurring around GLP-1 therapy can potentially involve several overlapping factors.
Depending on the individual, these may include:
Significant or rapid weight change
Reduced caloric intake
Changes in protein or nutrient intake
Physiologic stress associated with weight loss
Other medical or hormonal factors
Pre-existing androgenetic alopecia
This is why a temporal association with tirzepatide does not automatically prove that the medication itself is the sole cause.
In this case, the patient's years of hair loss before tirzepatide strongly suggested that an underlying hair-loss condition was already present.
Why Didn't Nutrafol or Xtresse Stop the Hair Loss?
This patient had already tried Nutrafol and Xtresse without achieving the improvement she wanted.
Supplements may be incorporated into some hair-loss treatment plans, but they do not address every cause of thinning.
In particular, supplements alone may not be enough to manage progressive follicular miniaturization from androgenetic alopecia.
When thinning continues despite supplements, identifying the underlying diagnosis becomes particularly important.
What Treatments Were Discussed?
Her consultation included several medical, device-based, and procedural options:
Topical minoxidil
Oral minoxidil
Spironolactone
Finasteride or dutasteride when appropriate
Low-level laser caps
PRP
Alma TED
After reviewing the options and potential side effects, she elected to begin oral minoxidil plus spironolactone.
What Dose of Oral Minoxidil Did She Start?
She was prescribed:
Minoxidil 2.5 mg tablets — take one-half tablet once daily.
That equals 1.25 mg of oral minoxidil per day.
Oral minoxidil is used off-label for hair loss.
It may be considered for selected patients with female pattern hair loss when a dermatologist determines that the potential benefits outweigh the risks.
Can Minoxidil Make Shedding Worse at First?
Yes.
This patient was counseled that temporary increased shedding may occur during approximately the first 8–10 weeks after beginning minoxidil.
This can be particularly confusing for someone who is already experiencing telogen effluvium.
Early shedding does not automatically mean the medication is failing.
Hair-growth treatments generally need to be evaluated over several months rather than several weeks.
What Side Effects Can Oral Minoxidil Cause?
Potential adverse effects reviewed included:
Unwanted facial or body hair growth
Dizziness
Lightheadedness
Low blood pressure
Increased heart rate
Headache
Ankle swelling
Fluid retention
Shortness of breath
The patient was instructed to discontinue treatment and contact the office if concerning symptoms such as chest pain, shortness of breath, ankle swelling, significant fluid retention, low blood pressure, increased heart rate, or significant dizziness develop.
Why Add Spironolactone?
The second part of this patient's treatment plan was spironolactone.
She was prescribed:
Spironolactone 50 mg twice daily.
Spironolactone has antiandrogen effects and is commonly considered off-label in appropriately selected women with female pattern hair loss.
While minoxidil is used to support hair growth and density, spironolactone addresses androgen-related signaling that can contribute to follicular miniaturization.
The combination therefore approaches AGA through different mechanisms.
What Are the Side Effects of Spironolactone?
Potential adverse effects discussed with this patient included:
Breast tenderness
Menstrual irregularities
Dizziness
Fatigue
Elevated potassium
Spironolactone can also lower blood pressure.
Importantly, spironolactone should not be taken during pregnancy.
Medication decisions should therefore account for pregnancy potential, other medications, kidney function, blood pressure, and the patient's overall medical history.
Why Does She Need Bloodwork Before Spironolactone?
The treatment plan included laboratory monitoring.
A comprehensive metabolic panel (CMP) was planned before treatment, with potassium rechecked approximately one month after starting spironolactone.
Spironolactone can increase potassium levels in the blood, so appropriate laboratory monitoring may be recommended based on the patient's age, health, dose, and other risk factors.
What About PRP or Alma TED?
Both PRP and Alma TED were discussed as procedural options.
PRP uses a platelet-rich preparation derived from the patient's own blood, which is then injected into targeted areas of the scalp.
Alma TED is a non-surgical, device-based hair-restoration treatment.
These approaches may be considered as part of a broader treatment strategy, but this patient elected to begin with medication.
Response varies with every hair-restoration treatment, and no procedure can guarantee complete regrowth.
Why Were Baseline Photos Taken?
Baseline clinical photographs were obtained during this patient's visit.
Hair changes occur slowly, making progress difficult to judge from memory alone.
Standardized photographs allow the dermatologist and patient to compare:
Overall density
Part width
Crown coverage
Scalp visibility
Progression or stabilization
The patient will return in approximately six months, when the new photographs can be compared with her baseline.
Does an Inflamed or Flaky Scalp Matter Too?
Yes.
This patient also had seborrheic dermatitis of the scalp.
Seborrheic dermatitis is a chronic inflammatory condition that can cause:
Flaking
Scaling
Itching
Redness
Scalp irritation
It can flare periodically, sometimes during periods of stress.
However, seborrheic dermatitis and androgenetic alopecia are separate conditions.
Controlling scalp inflammation is important, but treating seborrheic dermatitis does not reverse the follicular miniaturization of female pattern hair loss.
How Was Her Seborrheic Dermatitis Treated?
She was prescribed two treatments.
Ketoconazole 2% shampoo was recommended one to three times per week for maintenance. She was instructed to lather it into the scalp, leave it on for approximately 5–10 minutes, and then rinse.
She was also prescribed fluocinonide 0.05% solution, to be applied to affected areas of the scalp twice daily as needed for more severe flares.
Because fluocinonide is a topical corticosteroid, it was intended for flares rather than unrestricted continuous use.
Prolonged topical steroid use can cause skin thinning, pigment changes, and visible superficial blood vessels.
Should You Stop Tirzepatide if Your Hair Starts Falling Out?
That decision should not be made based on hair shedding alone without discussing it with the clinician prescribing the medication.
Hair loss can have multiple causes, and stopping a medication does not necessarily address underlying androgenetic alopecia.
Instead, an evaluation can help determine whether the patient has:
Telogen effluvium
Female pattern hair loss
Nutritional contributors
Another form of alopecia
More than one process occurring simultaneously
For this patient, the clinical assessment favored TE unmasking AGA, rather than assuming tirzepatide was solely responsible.
When Should You See a Dermatologist for Hair Loss on Tirzepatide?
Consider an evaluation if:
Your shedding increased after starting tirzepatide
Your hair was already thinning before starting a GLP-1 medication
Your center part is getting wider
Your crown is becoming more visible
You have lost significant hair density
Nutrafol or other supplements have not helped
You are experiencing scalp flaking or inflammation
You want to discuss minoxidil, spironolactone, PRP, or Alma TED
The timing of the shedding can provide an important clue, but it does not replace an examination.
Hair Loss Worse After Tirzepatide? There May Be More Than One Cause
For this 44-year-old woman, hair loss had been gradually progressing for years before she began micro-dosing tirzepatide six months earlier.
She felt that the thinning became worse afterward.
Rather than attributing everything to the medication, her clinical evaluation favored telogen effluvium unmasking underlying androgenetic alopecia.
After previously trying Nutrafol and Xtresse without satisfactory improvement, she elected to begin:
Oral minoxidil 1.25 mg daily
Spironolactone 50 mg twice daily
CMP and potassium monitoring
Baseline photography with reassessment in approximately six months
Her coexisting seborrheic dermatitis was addressed separately with ketoconazole shampoo and fluocinonide solution for significant flares.
Her case highlights an important point:
If your hair becomes noticeably thinner after starting tirzepatide, the medication may not be the entire story. A shedding episode can sometimes expose female pattern hair loss that had already been progressing quietly for years.
At Village Dermatology in Houston and Katy, Texas, we evaluate hair shedding associated with weight changes and GLP-1 therapy as well as female pattern hair loss, telogen effluvium, and inflammatory scalp conditions.
If your hair has become thinner since starting tirzepatide or another GLP-1 medication, a dermatologic hair-loss evaluation can help determine what may be contributing and which treatment options may be appropriate.
